Katrina K. Bakken
Mayo Clinic
PharmacodynamicsCancerInternal medicineDNA damageOncologyNeurosphereKinaseChemistryApoptosisIn vitroIn vivoMdm2GlioblastomaTemozolomideBlood–brain barrierCancer researchRadiation therapyMedicineBiologyPharmacologyDistribution (pharmacology)
43Publications
8H-index
294Citations
Publications 40
Newest
#1Jiajia Chen (Mayo Clinic)
#2Shiv K. Gupta (Mayo Clinic)H-Index: 8
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 11 authors...
The efficacy of standard radiation therapy (RT) in glioblastoma (GBM) is limited, and there is a strong rationale to develop effective radiosensitizing agents. ATM is a key regulator of DNA damage induced by RT, and small molecule ATM inhibitors have shown radio-sensitizing effects in cancer cells, and may improve radio-sensitivity in GBM. Here, we evaluated the brain penetrant ATM inhibitor AZD1390 in combination with RT in GBM cell lines and patient derived xenografts (PDXs). AZD1390 (30 nM an...
Source
#1Ann C. Mladek (Mayo Clinic)H-Index: 19
#2Shiv K. Gupta (Mayo Clinic)H-Index: 8
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 11 authors...
Cell survival following radiation therapy (RT) is critically modulated by multiple DNA damage response pathways including the p53 tumor suppressor, which promotes cell cycle arrest and/or apoptosis in the face of DNA damage. Murine Double Minute 2 (MDM2) targets p53 for degradation and suppresses its functions. The MDM2 locus is amplified in approximately 14% of glioblastoma (GBM) tumors and is a promising target for individualized therapy. In these studies, we tested the MDM2 small molecule inh...
1 CitationsSource
#1Danielle M. Burgenske (Mayo Clinic)H-Index: 2
#2Ann C. Mladek (Mayo Clinic)H-Index: 19
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 18 authors...
Lisavanbulin (LIS; BAL101553) is the prodrug of BAL27862, a microtubule-binding, tumor checkpoint controller and potential radiosensitizer. These studies evaluated optimal integration of LIS with standard of care radiation therapy (RT) and/or temozolomide (TMZ) using GBM PDX models. Distribution across the blood brain barrier was evaluated after a single 30 mg/kg oral LIS dose, and concentrations of the active metabolite BAL27862 were measured by liquid chromatography-tandem mass spectrometry. S...
Source
#1Susan Christine Massey (Mayo Clinic)H-Index: 8
#2Andrea Hawkins-Daarud (Mayo Clinic)H-Index: 15
Last. Kristin R. Swanson (Mayo Clinic)H-Index: 47
view all 20 authors...
1 CitationsSource
#1Hongxu Ding (Columbia University)H-Index: 5
#2Danielle M. Burgenske (Mayo Clinic)H-Index: 2
Last. Andrea Califano (Columbia University)H-Index: 76
view all 21 authors...
Glioblastoma heterogeneity and plasticity remain controversial, with proposed subtypes representing the average of highly heterogeneous admixtures of independent transcriptional states. Single-cell, protein-activity-based analysis allowed full quantification of >6,000 regulatory and signaling proteins, thus providing a previously unattainable single-cell characterization level. This helped identify four novel, molecularly distinct subtypes that successfully harmonize across multiple GBM datasets...
2 CitationsSource
#1Bianca M Marin (Mayo Clinic)H-Index: 2
#2Ann C. Mladek (Mayo Clinic)H-Index: 19
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 9 authors...
2 CitationsSource
Poly (ADP-ribose) polymerase PARP inhibitors, including talazoparib (TAL), potentiate temozolomide (TMZ) efficacy in multiple tumor types, however TAL-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates TAL ± TMZ in clinically relevant GBM models. TAL at 1-3 nmol/L sensitized T98G, U251 and GBM12 cells to TMZ, and enhanced DNA damage signaling and G2/M arrest in vitro. In vivo cyclical therapy with TAL (0.15 mg/kg twice daily) combined with...
29 CitationsSource
#1Gaspar J. KitangeH-Index: 27
#2Ann C. MladekH-Index: 19
Last. Jann N. SarkariaH-Index: 67
view all 6 authors...
Source
#1Cheyne Kurokawa (Mayo Clinic)H-Index: 6
#2Hirosha Geekiyanage (Mayo Clinic)H-Index: 7
Last. Evanthia Galanis (Mayo Clinic)H-Index: 68
view all 12 authors...
Aurora A kinase (AURKA), a member of the serine/threonine kinase family, plays a critical role in cell division, and it is widely overexpressed in a variety of tumors including glioblastoma (GBM). Alisertib (MLN8237) is an orally administered selective AURKA inhibitor with potent antiproliferative activity, currently undergoing clinical testing in different tumor types. In vitro evaluation of alisertib against the primary GBM lines, GBM6, GBM10, GBM12 and GBM39 showed significant antitumor activ...
15 CitationsSource
Source